Log In
BCIQ
Print this Print this
 

Ereska, ketamine (PMI-150)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionNon-opiate intranasal ketamine nmda receptor antagonist
Molecular Target NMDA receptor
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsEmergency analgesic for military and civilian use; Treat acute post-operative pain; Treat breakthrough cancer pain; Treat breakthrough pain; Treat moderate to severe pain; Treat moderate to severe post-operative pain
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,700.0M

$1,700.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/03/2015

$1,700.0M

$1,700.0M

0

Get a free BioCentury trial today